11/24
04:30 pm
tars
Tarsus to Participate in Upcoming Investor Conference
Medium
Report
Tarsus to Participate in Upcoming Investor Conference
11/20
01:57 pm
tars
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 [Seeking Alpha]
Low
Report
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 [Seeking Alpha]
11/20
08:43 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $100.00 price target on the stock.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $100.00 price target on the stock.
11/8
01:12 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at
Wall St
Medium
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at
Wall St
11/6
10:12 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
11/5
05:05 pm
tars
Tarsus to Participate in Upcoming Investor Conference
Low
Report
Tarsus to Participate in Upcoming Investor Conference
11/5
10:06 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target raised by analysts at Guggenheim from $84.00 to $87.00. They now have a "buy" rating on the stock.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target raised by analysts at Guggenheim from $84.00 to $87.00. They now have a "buy" rating on the stock.
11/4
04:05 pm
tars
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
Medium
Report
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
10/28
05:00 pm
tars
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Low
Report
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
10/25
12:12 pm
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/20
08:21 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/20
07:01 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was given a new $88.00 price target on by analysts at HC Wainwright.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was given a new $88.00 price target on by analysts at HC Wainwright.
10/1
01:48 pm
tars
Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight [Yahoo! Finance]
Low
Report
Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight [Yahoo! Finance]
9/26
01:06 pm
tars
Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off [Seeking Alpha]
Low
Report
Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off [Seeking Alpha]
9/9
05:56 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.